NRx Pharmaceuticals, Inc. ( NASDAQ:NRXP ) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

Benzinga
2025.09.24 13:07
portai
I'm PortAI, I can summarize articles.

适用性申请是将氯胺酮的多剂量包装转变为单患者剂量无防腐剂氯胺酮所必需的。批准适用性申请将使 NRx 的专利申请中的无防腐剂氯胺酮产品重新提交简化新药申请（ANDA）

Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.